Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ACBFF OTCMKTS:EVTCY NASDAQ:QURE NASDAQ:TARS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACBFFAurora Cannabis$2.67-0.7%$3.01$2.20▼$12.53$2.57BN/A4.22 million shs1.25 million shsEVTCYEvotec$1.96+2.1%$2.63$14.22▼$26.57$647.23M0.982,407 shs50,289 shsQUREuniQure$40.07+9.3%$36.75$8.73▼$71.50$2.31B0.91.33 million shs3.86 million shsTARSTarsus Pharmaceuticals$58.52-0.7%$61.31$38.51▼$85.25$2.54B0.51.38 million shs679,677 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACBFFAurora Cannabis0.00%-0.37%-5.65%-18.84%-44.14%EVTCYEvotec+2.08%-2.00%-28.47%-37.58%-53.99%QUREuniQure+9.30%-0.77%-15.45%+100.85%+192.91%TARSTarsus Pharmaceuticals-0.73%+1.63%-4.47%-8.00%+45.79%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACBFFAurora Cannabis$2.67-0.7%$3.01$2.20▼$12.53$2.57BN/A4.22 million shs1.25 million shsEVTCYEvotec$1.96+2.1%$2.63$14.22▼$26.57$647.23M0.982,407 shs50,289 shsQUREuniQure$40.07+9.3%$36.75$8.73▼$71.50$2.31B0.91.33 million shs3.86 million shsTARSTarsus Pharmaceuticals$58.52-0.7%$61.31$38.51▼$85.25$2.54B0.51.38 million shs679,677 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACBFFAurora Cannabis0.00%-0.37%-5.65%-18.84%-44.14%EVTCYEvotec+2.08%-2.00%-28.47%-37.58%-53.99%QUREuniQure+9.30%-0.77%-15.45%+100.85%+192.91%TARSTarsus Pharmaceuticals-0.73%+1.63%-4.47%-8.00%+45.79%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACBFFAurora Cannabis 0.00N/AN/AN/AEVTCYEvotec 0.00N/AN/AN/AQUREuniQure 2.71Moderate Buy$64.1760.14% UpsideTARSTarsus Pharmaceuticals 2.78Moderate Buy$90.5054.65% UpsideCurrent Analyst Ratings BreakdownLatest EVTCY, ACBFF, QURE, and TARS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/29/2026QUREuniQure Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradePeer Perform ➝ Outperform7/21/2026TARSTarsus Pharmaceuticals GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$90.00 ➝ $89.007/17/2026TARSTarsus Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/9/2026TARSTarsus Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$88.006/29/2026QUREuniQure HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$50.00 ➝ $80.006/26/2026QUREuniQure Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/25/2026QUREuniQure MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$35.00 ➝ $68.006/18/2026QUREuniQure Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$35.00 ➝ $65.006/18/2026QUREuniQure HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/18/2026QUREuniQure Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$36.00 ➝ $70.006/18/2026QUREuniQure The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$14.00 ➝ $46.00(Data available from 7/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACBFFAurora CannabisN/AN/AN/AN/AN/AN/AEVTCYEvotec$572.16M1.13$0.02 per share105.53$2.52 per share0.78QUREuniQure$16.10M156.97N/AN/A$3.19 per share12.56TARSTarsus Pharmaceuticals$451.36M5.58N/AN/A$8.09 per share7.23Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACBFFAurora CannabisN/A$0.1222.25N/AN/AN/AN/AN/AN/AEVTCYEvotec$7.14M$0.414.78N/AN/A20.85%16.02%7.81%N/AQUREuniQure-$198.97M-$3.48N/AN/AN/A-1,154.42%-145.81%-27.15%N/ATARSTarsus Pharmaceuticals-$66.42M-$1.14N/A23.04N/A-9.02%-14.19%-8.89%8/6/2026 (Estimated)Latest EVTCY, ACBFF, QURE, and TARS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026TARSTarsus Pharmaceuticals-$0.21N/AN/AN/A$169.11 millionN/A7/29/2026Q2 2026QUREuniQure-$0.8223-$1.22-$0.3977-$1.22$5.50 million$5.84 million5/6/2026Q1 2026TARSTarsus Pharmaceuticals-$0.4003-$0.16+$0.2403-$0.16$149.60 million$162.05 million5/5/2026Q1 2026QUREuniQure-$0.88-$0.85+$0.03-$0.85$5.21 million$3.56 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACBFFAurora CannabisN/AN/AN/AN/AN/AEVTCYEvotecN/AN/AN/AN/AN/AQUREuniQureN/AN/AN/AN/AN/ATARSTarsus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACBFFAurora CannabisN/AN/AN/AEVTCYEvotec0.532.572.50QUREuniQure0.3310.4010.40TARSTarsus Pharmaceuticals0.213.743.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACBFFAurora CannabisN/AEVTCYEvotecN/AQUREuniQure78.83%TARSTarsus Pharmaceuticals90.01%Insider OwnershipCompanyInsider OwnershipACBFFAurora CannabisN/AEVTCYEvotecN/AQUREuniQure4.65%TARSTarsus Pharmaceuticals9.64%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACBFFAurora Cannabis1,340960.96 millionN/ANot OptionableEVTCYEvotec4,200330.22 millionN/ANot OptionableQUREuniQure50063.07 million60.13 millionOptionableTARSTarsus Pharmaceuticals5043.02 million38.88 millionOptionableEVTCY, ACBFF, QURE, and TARS HeadlinesRecent News About These CompaniesTarsus Pharmaceuticals, Inc. (TARS) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseJuly 29 at 11:02 AM | zacks.comAlly Bridge Group NY LLC Acquires Shares of 80,859 Tarsus Pharmaceuticals, Inc. $TARSJuly 29 at 3:04 AM | marketbeat.comRock Springs Capital Management LP Sells 35,165 Shares of Tarsus Pharmaceuticals, Inc. $TARSJuly 28 at 6:56 AM | marketbeat.comLido Advisors LLC Makes New Investment in Tarsus Pharmaceuticals, Inc. $TARSJuly 27 at 5:03 AM | marketbeat.comCaxton Associates LLP Has $1.06 Million Holdings in Tarsus Pharmaceuticals, Inc. $TARSJuly 27 at 3:44 AM | marketbeat.comWalleye Capital LLC Reduces Holdings in Tarsus Pharmaceuticals, Inc. $TARSJuly 25, 2026 | marketbeat.comTarsus Pharmaceuticals: Q2 2026 Rebound In Sales Possible, Catalysts ApproachingJuly 24, 2026 | seekingalpha.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Consensus Rating of "Moderate Buy" from BrokeragesJuly 22, 2026 | americanbankingnews.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesJuly 22, 2026 | marketbeat.comTarsus Pushes into Retinal Market in $75M DealJuly 21, 2026 | ocbj.comOJennison Associates LLC Cuts Position in Tarsus Pharmaceuticals, Inc. $TARSJuly 19, 2026 | marketbeat.comGuggenheim Sticks to Its Buy Rating for Tarsus Pharmaceuticals (TARS)July 16, 2026 | theglobeandmail.comTarsus Pharmaceuticals (TARS) Replaces Its Commercial Chief While iRenix Talks ContinueJuly 15, 2026 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: UnitedHealth (UNH) and Tarsus Pharmaceuticals (TARS)July 15, 2026 | theglobeandmail.comTarsus Pharmaceuticals (TARS) Holds Steady Above Support as Resistance Looms - Volatility SurfaceJuly 14, 2026 | donanimhaber.comDTarsus Chief Commercial Officer DepartsJuly 14, 2026 | ocbj.comOTarsus Pharmaceuticals Announces Chief Commercial Officer TransitionJuly 13, 2026 | tipranks.comTarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of GrowthJuly 13, 2026 | globenewswire.comTarsus Pharmaceuticals, Inc. Common Stock (TARS)July 12, 2026 | nasdaq.comTarsus Pharmaceuticals (NASDAQ:TARS) Cut to "Hold" at Wall Street ZenJuly 12, 2026 | marketbeat.comARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadershipJuly 11, 2026 | biopharmadive.comBNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEVTCY, ACBFF, QURE, and TARS Company DescriptionsAurora Cannabis OTCMKTS:ACBFF$2.67 -0.02 (-0.74%) As of 07/24/2026Aurora Cannabis Inc is a Canada-based company engaged in the production and distribution of medical cannabis. The Company is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, home cultivation, wholesale and retail distribution. The Company's purpose-built facilities, which integrate technologies across all processes, are defined by automation and customization. The Company has a funded capacity of more than 500,000 kilograms per year, as well as sales and operations in more than 10 countries worldwide.Evotec OTCMKTS:EVTCY$1.96 +0.04 (+2.08%) As of 07/28/2026Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.uniQure NASDAQ:QURE$40.07 +3.41 (+9.30%) Closing price 07/29/2026 04:00 PM EasternExtended Trading$40.60 +0.53 (+1.32%) As of 04:50 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.Tarsus Pharmaceuticals NASDAQ:TARS$58.52 -0.43 (-0.73%) Closing price 07/29/2026 04:00 PM EasternExtended Trading$58.00 -0.52 (-0.89%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why SK hynix Could Be the Best AI Chip Stock to Buy Now Why Bloom Energy May Be the Most Important AI Infrastructure Stock Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead? Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters Broadcom’s $200 Billion Samsung Deal Shows How Costly the AI Memory Race Has Become Meta’s AI Spending Problem Just Found a BlackRock Solution Carrier Earnings Could Send the Stock to a New All-Time High Amazon’s Satellite Push Raises the Stakes for SpaceX and AST SpaceMobile Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
